Long noncoding RNA SNHG4 promotes glioma progression via regulating miR-367-3p/MYO1B axis in zebrafish xenografts

被引:0
作者
Zhang, Yueqing [1 ,2 ]
Wang, Yongjin [2 ]
Yang, Yang [2 ]
Sun, Chunming [1 ]
机构
[1] Soochow Univ, Dept Neurosurg, Affiliated Hosp 1, Suzhou 215006, Peoples R China
[2] Huaian Hosp Huaian City, Dept Neurosurg, Huaian 223200, Peoples R China
关键词
Glioma; LncRNA SNHG4; MiR-367-3p; MYO1B; Zebrafish xenograft; POOR-PROGNOSIS; PROLIFERATION; INVASION; GLIOBLASTOMA; CANCER; THERAPY; CELLS;
D O I
10.1007/s13577-025-01183-1
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Glioma is one of the most malignancy and prevalent tumor in the human central nervous system, which is associated with severe morbidity and high mortality. Numerous studies have explained the clear correlation between abnormal expression of lncRNA and progression of Glioma. LncRNA small nucleolar RNA host gene 4 (SNHG4) have been proved to play oncogenesis roles in various tumors, however, the underlying mechanism remains to be explored deeply. In this study, by analysis of the public database, we found that SNHG4 was upregulated in multiple cancer tissues, including glioma. Subsequently, the functional roles of SNHG4 were investigated, and we found that knockdown of SNHG4 remarkedly inhibited cell proliferation, migration. While, overexpression of SNHG4 enhanced these functions of glioma cells in vitro. Meanwhile, as the in vivo tool, zebrafish xenograft model was used to verify the functions of SNHG4 in glioma cells. Mechanically, we identified that SNHG4 or MYO1B could bind with miR-367-3p by the luciferase reporter assays. Furthermore, the rescue experiments showed that the inhibition of miR-367-3p or the expression of MYO1B partially rescue the inhibition effects of SNHG4 in glioma cells. Our study reveals that SNHG4 promotes the proliferation, migration of glioma via regulating miR-367-3p/MYO1B axis.
引用
收藏
页数:18
相关论文
共 70 条
  • [1] Tan A.C., Ashley D.M., Lopez G.Y., Malinzak M., Friedman H.S., Khasraw M., Management of glioblastoma: state of the art and future directions, CA Cancer J Clin, 70, 4, pp. 299-312, (2020)
  • [2] Schaff L.R., Mellinghoff I.K., Glioblastoma and other primary brain malignancies in adults: a review, JAMA, 329, 7, pp. 574-587, (2023)
  • [3] Lu X., Zhang D., Expression of lncRNAs in glioma: a lighthouse for patients with glioma, Heliyon, 10, 3, (2024)
  • [4] Quan J., Qu J., Zhou L., MicroRNA-539 inhibits glioma cell proliferation and invasion by targeting DIXDC1, Biomed Pharmacother, 93, pp. 746-753, (2017)
  • [5] Popescu I.D., Codrici E., Albulescu L., Et al., Potential serum biomarkers for glioblastoma diagnostic assessed by proteomic approaches, Proteome Sci, 12, 1, (2014)
  • [6] Sathornsumetee S., Reardon D.A., Desjardins A., Quinn J.A., Vredenburgh J.J., Rich J.N., Molecularly targeted therapy for malignant glioma, Cancer, 110, 1, pp. 13-24, (2007)
  • [7] Geraldo L.H.M., Garcia C., da Fonseca A.C.C., Et al., Glioblastoma therapy in the age of molecular medicine, Trends Cancer, 5, 1, pp. 46-65, (2019)
  • [8] Finishing the euchromatic sequence of the human genome, Nature, 431, 7011, pp. 931-945, (2004)
  • [9] Djebali S., Davis C.A., Merkel A., Et al., Landscape of transcription in human cells, Nature, 489, 7414, pp. 101-108, (2012)
  • [10] Wilusz J.E., Sunwoo H., Spector D.L., Long noncoding RNAs: functional surprises from the RNA world, Genes Dev, 23, 13, pp. 1494-1504, (2009)